Citius Oncology, Inc. CTOR Inprocess Research And Development Noncurrent
Inprocess Research And Development Noncurrent at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept ctor:InprocessResearchAndDevelopmentNoncurrent.
The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s inprocess research and development noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s inprocess research and development noncurrent?
- Citius Oncology, Inc. (CTOR) reported inprocess research and development noncurrent of $71.11M in Q1 2026.
- How has Citius Oncology, Inc.'s inprocess research and development noncurrent changed year-over-year?
- Citius Oncology, Inc.'s inprocess research and development noncurrent decreased by 3.1% year-over-year, from $73.4M to $71.11M.
- What does inprocess research and development noncurrent mean?
- Represents the capitalized value of research and development projects acquired in business combinations that have not yet reached technological feasibility. This asset reflects the long-term investment in future product pipelines and potential commercial revenue streams. It is a critical indicator of a company's commitment to innovation and future growth potential in the pharmaceutical sector.